Small molecule · Cytotoxic · developed by Neonc Technologies
NEO212 is an orally bioavailable conjugate of temozolomide, a prodrug alkylating agent, with perillyl alcohol. Temozolomide is converted to MTIC, which methylates tumor cell DNA, and the conjugate is reported to cross the blood-brain barrier. It is being studied in glioma, brain metastases, and a range of solid tumors including gastrointestinal, head and neck, gynecologic and melanoma indications.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06047379 | Phase 1/2 | Diffuse Astrocytoma, IDH-Mutant | Recruiting | NTHI |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Brain Metastases, AdultCervical CancerColorectal CancerDiffuse Astrocytoma, IDH-MutantEsophageal CancerEsophageal Squamous Cell CarcinomaGastric CancerGastroesophageal Junction AdenocarcinomaGlioblastoma, IDH-wildtypeHead and Neck Squamous Cell CarcinomaMelanomaMerkel Cell CarcinomaMicrosatellite Instability-High Colorectal CancerMicrosatellite Instability-High Solid Malignant Tumor
Updated Oct 25, 2026. Something wrong or missing? Report it on the NTHI page.
See NTHI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NTHI catalysts and pipeline →